Procurement Summary
Country : USA
Summary : 10X Xenium Assay Kits
Deadline : 29 Jul 2024
Other Information
Notice Type : Tender
TOT Ref.No.: 104483862
Document Ref. No. : RFQ-NIAID-24-2230838
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
Description
Description:
This notice is a Combined Synopsis/Solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 “Streamlined Procedures for Evaluation and solicitation for commercial Items, ” as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIAID-24-2230838 and the solicitation is issued as a Request for Quote (RFQ).
This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2024-05, May 22, 2024.
The North American Industry Classification System (NAICS) code for this procurement is 325414, Biological Product (except Diagnostic) Manufacturing, with a size standard of 1250 employees. The requirement is being competed with a brand name restriction, and with a small business set-aside.
The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for the following Brand Name Supplies:
Xenium Prime 5K Human Pan Tissue and Pathways Assay Kit (2 rxns), Product # 1000671, qty - 4
2. Xenium Prime 5K Add-on Custom 51 to 100 Gene Panel (12 rxns) - CDP# 8PZ6EC, Product # 1000766, qty - 1
3. Shipping and Handling, qty 1
The Neuroimmunological Disease Section mission is to provide is to understand, diagnose, prognosticate, and cure neuroimmunological diseases. More recently, there is a major focus on developing mechanisms that participate in central nervous system (CNS) injury and those that have neuroprotective functions, we aim to develop effective therapies for neuroimmunological diseases. Xeni...
Active Contract Opportunity Notice ID RFQ-NIAID-24-2230838 Related Notice Department/Ind. Agency HEALTH AND HUMAN SERVICES, DEPARTMENT OF Sub-tier NATIONAL INSTITUTES OF HEALTH Office NATIONAL INSTITUTES OF HEALTH NIAID
General Information
Contract Opportunity Type: Combined Synopsis/Solicitation (Original)
All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
Original Published Date: Jul 19, 2024 05:54 pm EDT
Original Date Offers Due: Jul 29, 2024 11:00 am EDT
Inactive Policy: 15 days after date offers due
Original Inactive Date: Aug 13, 2024
Initiative: None
Classification
Original Set Aside:
Product Service Code: 6550 - IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS
NAICS Code: 325414 - Biological Product (except Diagnostic) Manufacturing
Place of Performance: Bethesda, MD 20892 USA
Documents
Tender Notice
2_Terms_and_Conditions_RFQ-NIAID-24-2230838_FAR_52.212-5_MAY_2024.pdf